Breaking Finance News

Chardan Capital disclosed Amicus Therapeutics (NDAQ:FOLD), bumping down its price target to $16.50 earlier today

Having a price of $13.60, Amicus Therapeutics (NDAQ:FOLD) traded 2.00% higher on the day. With the last close up 40.97% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. FOLD has recorded a 50-day average of $13.21 and a two hundred day average of $9.61. Trade Volume was up over the average, with 6,963,442 shares of FOLD changing hands over the typical 3,673,900

Reporting a potential upside of 0.21%, Chardan Capital dropped the price target of Amicus Therapeutics (NDAQ:FOLD) to $16.50

On Thursday August 10, 2017, Chardan Capital released a statement on Amicus Therapeutics (NDAQ:FOLD) upped the target price from $12.50 to $17.50 that suggested an upside of 0.47%.

Recent Performance Chart

Amicus Therapeutics (NDAQ:FOLD)

Amicus Therapeutics has with a one year low of $4.41 and a one year high of $14.37 and has a market capitalization of $0.

A total of 7 analysts have released a report on Amicus Therapeutics. Two analysts rating the company a strong buy, three analysts rating the company a buy, two analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $13.00.

General Company Details For Amicus Therapeutics (NDAQ:FOLD)

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.